Journal
JOURNAL OF GERIATRIC ONCOLOGY
Volume 8, Issue 4, Pages 237-241Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jgo.2017.04.003
Keywords
Melanoma; Checkpoint inhibitors; Ipilimumab; Nivolumab; Pembrolizumab; Immune-related adverse events
Categories
Funding
- BMS
Ask authors/readers for more resources
The incidence of melanoma and associated mortality rate from advanced disease in older adults is increasing over time. Checkpoint inhibitors have demonstrated a survival benefit for the treatment of stage IV or unresectable stage III disease and have become one of the standards of care. Data suggests that adults aged 65 and older benefit from treatment with checkpoint inhibitors without an increased incidence in adverse events. However, clinicians should be aware of the potential side effects of this class of medications and how to manage them in older adults. (C) 2017 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available